Zantac Judge Recusal Fight: Philadelphia Judge Again Refuses to Step Aside Over Wife's Blank Rome Ties
In a supplemental opinion reported Nov. 10-11, 2026, Philadelphia Judge Joshua Roberts again refused to recuse from the city's 500-plus Zantac cases, saying a settlement removed Apotex, the only defendant his wife's firm represented. Keller Postman's Superior Court appeal remains the real test.
Torts Desk··13 min read

The Philadelphia judge who runs the city's Zantac mass tort has refused, for a third time, to step aside: in a supplemental opinion reported on Nov. 10 and 11, 2026, Judge Joshua Roberts of the Philadelphia Court of Common Pleas said a settlement had eliminated the claims against Apotex Corp., the only Zantac defendant represented by Blank Rome, the firm where his wife is a partner. The Zantac judge recusal fight now turns on a pending Pennsylvania Superior Court appeal brought by a Keller Postman client, and on whether that court treats the Apotex settlement as ending the dispute or as beside the point.
For the more than 500 plaintiffs whose ranitidine cancer claims sit in Philadelphia, the practical question is not ethics in the abstract. It is whether the docket, which the judge himself said in July had been left to "languish," starts moving again, and in front of whom.
What happened: the November 2026 supplemental opinion
Law360 reported on Nov. 10, 2026 that the Pennsylvania state judge overseeing Philadelphia's Zantac litigation had again rejected arguments that he might be conflicted because his wife's firm represents a defendant in one of the more than 500 cases. The answer he gave was short: the case in question has been resolved. Mealey's followed on Nov. 11, describing the ruling as a supplemental opinion in which Roberts reiterated his impartiality and explained that a settlement had eliminated the claims against Apotex, the only defendant in the proceedings represented by his wife's law firm.
The opinion is the latest entry in a Zantac judge recusal dispute that has run since 2024 and has spanned two law firms. Mealey's listing for the ruling also attaches a notice of appeal, a motion to recuse and a memorandum supporting that motion, which signals that the record now in front of the appellate court includes both sides' filings on the Blank Rome theory. The full text sits behind paywalls and on the court's docket; the reasoning summarized here comes from the published reports and from Roberts's earlier written rulings on the same issue.
The point of a supplemental opinion at this stage is to tell the reviewing court what has changed since the original order. Roberts's April 2026 denial rested partly on the fact that Apotex was not a defendant in the specific case that generated the appeal. The November filing adds a second, independent answer: even across the whole mass tort, Apotex is gone.
Who is the judge overseeing the Philadelphia Zantac cases?
Judge Joshua Roberts of the Philadelphia Court of Common Pleas presides over the consolidated Zantac (ranitidine) mass tort, which various reports have sized at roughly 550 to 600 cases. In his January 2025 written opinion, Roberts referred to his "oversight of the entire mass torts program," reflecting his supervisory role over Philadelphia's complex litigation docket, one of the busiest state-court mass tort venues in the country.
That supervisory role is part of why the recusal fight matters beyond Zantac. A judge who manages the program sets case management orders, trial pools and scheduling for multiple dockets. Roberts himself suggested in January 2025 that a more cynical reading of the first motion was that plaintiffs' counsel was mounting "a broadside against my oversight of the entire mass torts program."
What is the conflict of interest alleged in the Zantac mass tort?
The alleged conflict runs through the judge's wife, Shannon McClure, a defense-side partner at large firms that have represented Zantac manufacturers.
- Round one (Reed Smith). In 2024, plaintiffs' lawyers argued that McClure's partnership at Reed Smith created an appearance problem because Reed Smith represented GlaxoSmithKline (GSK) in Zantac litigation in other jurisdictions. Reed Smith's GSK work was outside Philadelphia, and the firm had placed an ethical wall around McClure for GSK matters. Plaintiffs did not allege she worked on Zantac.
- Round two (Blank Rome). McClure joined Blank Rome as a partner in February 2025, while the first denial was on appeal. Blank Rome represents Apotex in one Philadelphia Zantac case. Keller Postman filed a renewed motion in December 2025 arguing the new partnership gave the judge a financial interest that could be affected by the litigation.
Roberts's position throughout has been that neither link creates a disqualifying interest. In the April 2026 ruling he called any economic interest he had through the connection, at best, "exceptionally attenuated to the point of being nearly non-existent," relying in part on a statement from Blank Rome's Terry Henry that McClure's compensation is not directly tied to Apotex.
Timeline: the Zantac judge recusal fight, 2023 to 2026
| Date | Event | Source of report |
|---|---|---|
| Dec. 2023 | Roberts discloses his wife's Reed Smith partnership to counsel | Legal Intelligencer (Jan. 2025 opinion) |
| May-July 2024 | Plaintiffs, including Anapol Weiss and co-counsel, move for recusal over Reed Smith's GSK work | Legal Intelligencer; Anapol Weiss |
| Aug. 2024 | Roberts denies recusal and urges prompt appellate review | Law.com |
| Jan. 2025 | Written opinion calls the theory "hopeful supposition in the form of discordant dots" | Legal Intelligencer |
| Feb. 2025 | McClure becomes a partner at Blank Rome, which represents Apotex in one case | Legal Newsline; Law360 |
| Dec. 2025 | Keller Postman files renewed recusal motion based on Blank Rome | Legal Newsline |
| Apr. 15, 2026 | Roberts denies the renewed motion: Apotex not a defendant in the case at issue; motion untimely | Law360 (Apr. 21) |
| ~Apr. 23, 2026 | Keller Postman client appeals to the Pennsylvania Superior Court | Law360; Mealey's |
| May 2026 | Roberts declines to stay the Zantac litigation pending appeal | Law360 (May 21); HarrisMartin |
| July 2026 | Roberts says the recusal campaign has slowed the docket and left cases to "languish" | Law360 (July 23) |
| Nov. 10-11, 2026 | Supplemental opinion: Apotex claims eliminated by settlement; no basis for recusal | Law360; Mealey's |
The table shows a pattern that matters for the appeal. Each motion followed a disclosure by months, and each denial rested partly on timing. That is not an accident of drafting; Pennsylvania law makes delay fatal to a recusal claim.
Why won't the Philadelphia Zantac judge recuse himself?
Roberts has given four overlapping reasons across his rulings, and the November opinion adds a fifth.
- No real interest. A spouse's partnership share at a large firm, on his account, is too remote from the outcome of any single Zantac case to give the judge a stake in it. The Blank Rome statement that McClure's pay is not tied to Apotex supports that view.
- Wrong case. Apotex was not a defendant in the case on appeal, so Blank Rome was not counsel in the proceeding where recusal was sought.
- Waiver by the lawyers who were in the case. According to the Bressler risk blog's account of the April ruling, Roberts found that Anapol Weiss, the firm that originally filed the case on appeal, never sought recusal on the Blank Rome ground.
- Untimeliness. Roberts disclosed the Blank Rome move and Keller Postman waited about eight months to file. In 2024, he noted a five-month gap between his disclosure of the Reed Smith role and the motion.
- Mootness in fact. The November supplemental opinion reports that the only Blank Rome client in the mass tort has settled out.
Roberts has also leaned on the presumption in Pennsylvania law that judges are "honorable, fair and competent," and has used footnotes to push back. In the April ruling he suggested that Keller Postman's "ongoing and seemingly never-ending campaign" for his removal could sit uneasily with a lawyer's obligation to expedite clients' cases.
The legal test for Zantac judge recusal: Rule 2.11, de minimis interests and Lomas v. Kravitz
Pennsylvania's Code of Judicial Conduct, Rule 2.11, requires a judge to disqualify in any proceeding in which the judge's impartiality "might reasonably be questioned." The rule then lists specific situations, including where the judge knows that the judge's spouse or domestic partner is a party, a lawyer in the proceeding, or a person with more than a de minimis interest that could be substantially affected by the proceeding. The Code defines "economic interest" as more than a de minimis legal or equitable ownership interest.
Two features of that framework explain Roberts's approach. First, McClure is not counsel of record in the Zantac cases, so the clearest spousal trigger, a spouse acting as a lawyer in the proceeding, does not apply on the reported facts. Second, the de minimis and "substantially affected" language asks whether the outcome of this proceeding could move the spouse's finances in a meaningful way. A partner's interest in one client's single case, inside a firm of Blank Rome's size, is the kind of indirect interest that courts usually treat as too small, absent evidence of direct compensation.
Federal law uses nearly identical language. Under 28 U.S.C. § 455(b)(5)(iii), a federal judge must step aside when the judge knows a spouse has "an interest that could be substantially affected by the outcome of the proceeding." Federal courts have generally held that a spouse's partnership at a firm appearing in a case does not, by itself, require disqualification when the spouse does not work on the matter and the fee effect is remote, though appearance-based recusal under § 455(a) remains a separate question.
The timing rule is where Pennsylvania is stricter than many jurisdictions. In Lomas v. Kravitz, 170 A.3d 380 (Pa. 2017), the Pennsylvania Supreme Court held that a party must seek recusal "at the earliest possible moment," meaning when it knows the facts that form the basis for the motion. The court found that a 39-day delay waived the claim and declined to reach the merits. Measured against that standard, gaps of five and eight months are difficult for a movant to defend, which is why the Superior Court could affirm on waiver without ever addressing whether a judge's spouse's partnership creates an appearance problem.
Appellate review of a recusal denial in Pennsylvania is for abuse of discretion, and the movant bears the burden of producing evidence of bias, prejudice or unfairness. The Supreme Court of the United States has set a constitutional floor only in extreme cases, such as Caperton v. A.T. Massey Coal Co. (2009), where a litigant's outsized campaign spending created a serious risk of actual bias. Nothing in the reported Zantac record approaches that line.
Is the Zantac recusal appeal still pending in the Superior Court?
Yes, on the available reports. No published source through Nov. 13, 2026 reports a Superior Court decision on the Keller Postman appeal from the April 15, 2026 order. The November supplemental opinion appears designed to inform that court that the Apotex claims are gone.
The Apotex settlement creates a mootness question in the Zantac judge recusal appeal that the appellate panel will have to confront. If the only Blank Rome client has left the litigation, the argument that the judge has a spousal interest "that could be substantially affected" loses its object going forward. Keller Postman can still argue that the appearance problem tainted rulings made while Apotex was in the case, or that the pattern across two firms shows a broader issue. But the strongest version of the Blank Rome theory now looks backward, not forward, and a reviewing court can decline to order prospective recusal when the asserted conflict no longer exists.
How does the recusal fight affect Zantac trials in Philadelphia?
It has slowed them. Case trackers report that Philadelphia trial settings originally expected in 2025 were pushed back while the first recusal ruling was under appellate review. In May 2026, Roberts refused to stay proceedings during the second appeal, which on paper keeps the docket moving. By July 23, 2026, however, Law360 reported him saying that Keller Postman's effort had effectively halted the docket and left plaintiffs' cases to "languish."
The tension in those two positions is real. A trial judge can deny a stay, but defendants and plaintiffs alike may be reluctant to invest in trial preparation, expert work or settlement negotiation while an appellate court decides whether the judge should be presiding at all. A ruling against recusal would let Roberts set firm trial dates; a ruling for recusal would send the program to a new judge and could invite challenges to earlier orders.
Are Zantac lawsuits still active in 2026?
Yes, but the national docket is much smaller than it was. The Philadelphia mass tort is one of the larger remaining pockets of active state-court Zantac litigation.
| Forum | Status (as reported) |
|---|---|
| Federal MDL 2924 (S.D. Fla., Judge Robin Rosenberg) | December 2022 ruling excluded plaintiffs' general causation experts; appeal to the Eleventh Circuit argued in October 2025 and reported as still pending |
| Delaware Superior Court | Delaware Supreme Court reversed a pro-plaintiff expert ruling on July 10, 2025; in April 2026 the trial court granted summary judgment on general causation for cases filed on or before Dec. 1, 2025 |
| Philadelphia Court of Common Pleas | More than 500 cases before Judge Roberts; recusal appeal pending in the Superior Court |
| Settlements | GSK agreed in October 2024 to pay up to $2.2 billion to resolve about 80,000 state-court cases (about 93% of its state cases); Pfizer agreed in 2024 to settle more than 10,000 cases; Sanofi agreed to pay more than $100 million to resolve about 4,000 cases |
The Delaware result is the backdrop to everything happening in Philadelphia. Once a state court finds plaintiffs cannot establish general causation, the remaining dockets carry more weight, and the identity of the judge who will rule on expert admissibility in Philadelphia becomes a high-stakes question for both sides. That context helps explain why plaintiffs' counsel has pressed recusal across two firms and two years, and why defendants have been content to let the trial judge's rulings stand.
What it means for claimants' counsel, defendants and defense firms
For claimants' counsel in Philadelphia. The Lomas waiver rule is the lesson of the Zantac judge recusal saga. Any firm that believes a judge's family ties create a problem has to move promptly after the disclosure, build a record of actual financial linkage and avoid arguments that depend on a series of inferences. Two recusal rounds built on long delays have produced a docket the judge describes as stalled and a growing set of written findings about the movant's tactics.
For Zantac plaintiffs. Settlement leverage in a mass tort depends on credible trial dates. A pending recusal appeal suppresses that leverage for every plaintiff on the docket, not only the client whose case is on appeal. Plaintiffs represented by other firms may want their counsel to explain how the appeal affects their own timelines.
For defendants. The settlement that took Apotex out of the litigation also removed the only factual hook for the Blank Rome theory. Defendants that settle individual cases while a recusal appeal is pending can change the factual premise of that appeal; the November opinion shows a trial court using exactly that development.
For defense firms with judicial spouses. Ethical walls, documented compensation structures that are not tied to particular clients and early disclosure on the record were all cited in Roberts's rulings. Firms that hire partners married to sitting mass tort judges should expect those measures to be tested in a motion, and should be prepared to provide a sworn statement like the one Blank Rome supplied.
For litigation funders and portfolio investors. Duration risk in state-court mass torts includes judicial-assignment risk. A recusal appeal like the Zantac judge recusal fight can add a year or more to a docket without any ruling on the merits, and that delay compounds the general-causation risk already visible in the federal and Delaware outcomes.
FAQ
Why won't the Philadelphia Zantac judge recuse himself?
Judge Joshua Roberts says his wife's partnership at Blank Rome gives him no meaningful financial interest in the Zantac cases, that the only Blank Rome client, Apotex, has now settled out, and that the recusal motions were untimely under Pennsylvania law.
What did the Zantac judge's November 2026 supplemental opinion say?
Reported on Nov. 10 and 11, 2026, it reaffirmed Roberts's impartiality and explained that a settlement eliminated the claims against Apotex Corp., the only defendant in the Philadelphia Zantac proceedings represented by his wife's law firm.
Who filed the recusal appeal?
A plaintiff represented by Keller Postman appealed the April 15, 2026 denial to the Pennsylvania Superior Court on or about April 23, 2026; the case on appeal had originally been filed by Anapol Weiss in 2021.
When must a recusal motion be filed in Pennsylvania?
Under Lomas v. Kravitz, 170 A.3d 380 (Pa. 2017), a party must seek recusal at the earliest possible moment after learning the facts that support it; the Pennsylvania Supreme Court held a 39-day delay waived the claim.
How does the recusal fight affect Zantac trials in Philadelphia?
Trial settings have slipped while appellate review of the recusal rulings is pending, and Roberts said in July 2026 that the campaign had left plaintiffs' cases to "languish," even though he declined to formally stay the litigation.
Are Zantac lawsuits still active in 2026?
Yes. More than 500 cases remain in Philadelphia, the federal MDL's causation ruling is on appeal in the Eleventh Circuit, and Delaware's trial court granted summary judgment on general causation in April 2026, while GSK, Pfizer and Sanofi have settled most of their earlier inventories.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Keller Postman Sanctions Appeal: Kenvue Says Tylenol Lead Counsel Wants a New MDL Judge
Kenvue has told the Second Circuit that Ashley Keller's appeal of a May 8 protective-order sanction is a bid to move the revived Tylenol autism MDL away from Judge Denise Cote. The sanction was $50,000 to charity; the real stakes are who presides over 500-plus remanded cases.
Courts Desk · 14 min

Paraquat Litigation Funding Disclosure: MDL Judge Orders Smith Law Firm to Reveal Who Funds Its Cases
On October 14, 2026, Judge Nancy Rosenstengel ordered R. Allen Smith to disclose who funds his paraquat cases after only 49 of his 750 clients joined the Syngenta-Chevron settlement. The order ties litigation funding disclosure directly to settlement consent.
Torts Desk · 20 min

MDL Statistics October 2026: Talc Holds 69,340 Cases as Uber's Docket Jumps by 328 in a Month
The JPML's MDL statistics for October 2026 list 162 dockets, with Johnson & Johnson talc at 69,340 pending actions. Uber's sexual assault MDL added 328 cases in a month, hair relaxer added 252, and Depo-Provera and GLP-1 barely moved.
Torts Desk · 20 min